Alan T Nurden

List of Publications by Year
in descending order

93 papers	6,884 citations	76326 40 h-index	58581 82 g-index
94 all docs	94 docs citations	94 times ranked	6346 citing authors

#	Article	IF	Citations
1	Profiling the Genetic and Molecular Characteristics of Glanzmann Thrombasthenia: Can It Guide Current and Future Therapies?. Journal of Blood Medicine, 2021, Volume 12, 581-599.	1.7	3
2	Inherited platelet diseases with normal platelet count: phenotypes, genotypes and diagnostic strategy. Haematologica, 2021, 106, 337-350.	3.5	35
3	Healing through the lens of immunothrombosis: Biology-inspired, evolution-tailored, and human-engineered biomimetic therapies. Biomaterials, 2021, 279, 121205.	11.4	5
4	Inherited thrombocytopenias: history, advances and perspectives. Haematologica, 2020, 105, 2004-2019.	3.5	42
5	More than 500Âmillion years of evolution in a fibrin-based therapeutic scaffold. Regenerative Medicine, 2020, 15, 1493-1498.	1.7	4
6	Clinical significance of altered collagen-receptor functioning in platelets with emphasis on glycoprotein VI. Blood Reviews, 2019, 38, 100592.	5.7	35
7	A Glanzmann thrombasthenia family associated with a TUBB1â€related macrothrombocytopenia. Journal of Thrombosis and Haemostasis, 2019, 17, 2211-2215.	3.8	14
8	Is the mysterious platelet receptor GPV an unsuspected major target for platelet autoantibodies?. Haematologica, 2019, 104, 1103-1105.	3.5	3
9	Acquired Glanzmann thrombasthenia: From antibodies to anti-platelet drugs. Blood Reviews, 2019, 36, 10-22.	5.7	20
10	Autologous fibrin scaffolds: When platelet- and plasma-derived biomolecules meet fibrin. Biomaterials, 2019, 192, 440-460.	11.4	92
11	In silico analysis of structural modifications in and around the integrin Î±<scp>II</scp>b genu caused by <scp>ITGA</scp>2B variants in human platelets with emphasis on Glanzmann thrombasthenia. Molecular Genetics & Genomic Medicine, 2018, 6, 249-260.	1.2	6
12	A novel variant Glanzmann thrombasthenia due to co-inheritance of a loss- and a gain-of-function mutation of ITGB3 : evidence of a dominant effect of gain-of-function mutations. Haematologica, 2018, 103, e259-e263.	3.5	16
13	High-throughput sequencing for rapid diagnosis of inherited platelet disorders: a case for a European consensus. Haematologica, 2018, 103, 6-8.	3.5	8
14	Marked bleeding diathesis in patients with platelet dysfunction due to a novel mutation in RASGRP2, encoding CalDAG-GEFI (p.Gly305Asp). Platelets, 2018, 29, 84-86.	2.3	20
15	Mutations of the integrin Î±IIb/Î²3 intracytoplasmic salt bridge cause macrothrombocytopenia and enlarged platelet Î±â€granules. American Journal of Hematology, 2018, 93, 195-204.	4.1	17
16	ITGA2B and ITGB3 gene mutations associated with Glanzmann thrombasthenia. Platelets, 2018, 29, 98-101.	2.3	32
17	Personal reflections on the early contributions of Gus Born to platelet research. Platelets, 2018, 29, 756-760.	2.3	1
18	Acquired Antibodies to Î± IIbÎ²3 in Glanzmann Thrombasthenia: From Transfusion and Pregnancy to Bone Marrow Transplants and Beyond. Transfusion Medicine Reviews, 2018, 32, 155-164.	2.0	10

#	Article	IF	Citations
19	The biology of the platelet with special reference to inflammation wound healing and immunity. Frontiers in Bioscience - Landmark, 2018, 23, 726-751.	3.0	97
20	Management of pregnancy for a patient with the new syndromic macrothrombocytopenia, DIAPH1-related disease. Platelets, 2018, 29, 737-738.	2.3	4
21	Should studies on Glanzmann thrombasthenia not be telling us more about cardiovascular disease and other major illnesses?. Blood Reviews, 2017, 31, 287-299.	5.7	21
22	Phenotype analysis and clinical management in a large family with a novel truncating mutation in RASGRP2, the CalDAGâ€GEFI encoding gene. Research and Practice in Thrombosis and Haemostasis, 2017, 1, 128-133.	2.3	14
23	A Cdc42/RhoA regulatory circuit downstream of glycoprotein Ib guides transendothelial platelet biogenesis. Nature Communications, 2017, 8, 15838.	12.8	50
24	An intracytoplasmic Î²3 Leu718 deletion in a patient with a novel platelet phenotype. Blood Advances, 2017, 1, 494-499.	5.2	13
25	A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders. Blood, 2016, 127, 2791-2803.	1.4	157
26	Linkage disequilibrium amongst <scp>ITGA</scp>2B and <scp>ITGB</scp>3 gene variants in patients with Glanzmann thrombasthenia confirms that most diseaseâ€causing mutations are recent. British Journal of Haematology, 2016, 175, 686-695.	2.5	12
27	Should any genetic defect affecting Î±â€granules in platelets be classified as gray platelet syndrome?. American Journal of Hematology, 2016, 91, 714-718.	4.1	25
28	A gain-of-function variant in DIAPH1 causes dominant macrothrombocytopenia and hearing loss. Blood, 2016, 127, 2903-2914.	1.4	121
29	Defects in TRPM7 channel function deregulate thrombopoiesis through altered cellular Mg2+ homeostasis and cytoskeletal architecture. Nature Communications, 2016, 7, 11097.	12.8	84
30	Expanding the Mutation Spectrum Affecting Î±IIbÎ²3 Integrin in Glanzmann Thrombasthenia: Screening of theITGA2BandITGB3Genes in a Large International Cohort. Human Mutation, 2015, 36, 548-561.	2.5	67
31	Human phenotype ontology annotation and cluster analysis to unravel genetic defects in 707 cases with unexplained bleeding and platelet disorders. Genome Medicine, 2015, 7, 36.	8.2	119
32	Î±IIbÎ²3 variants defined by next-generation sequencing: Predicting variants likely to cause Glanzmann thrombasthenia. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1898-907.	7.1	36
33	Platelets: 25 years under the editorship of Stan Heptinstall. Platelets, 2015, 26, 378-381.	2.3	0
34	Phosphatidylserine exposure, microparticle formation and mitochondrial depolarisation in Glanzmann thrombasthenia platelets. Thrombosis and Haemostasis, 2014, 111, 1184-1186.	3.4	5
35	Mutation spectrum and genotypeâ€phenotype correlations in a large French cohort of <scp>MYH</scp>9â€Related Disorders. Molecular Genetics & Genomic Medicine, 2014, 2, 297-312.	1.2	78
36	Congenital platelet disorders and understanding of platelet function. British Journal of Haematology, 2014, 165, 165-178.	2.5	99

#	Article	IF	Citations
37	Spectrum of the Mutations in Bernard-Soulier Syndrome. Human Mutation, 2014, 35, 1033-1045.	2.5	124
38	Human CalDAG-GEFI gene (RASGRP2) mutation affects platelet function and causes severe bleeding. Journal of Experimental Medicine, 2014, 211, 1349-1362.	8.5	117
39	Procoagulant Platelets Form an Î±-Granule Protein-covered â€œCapâ€•on Their Surface That Promotes Their Attachment to Aggregates. Journal of Biological Chemistry, 2013, 288, 29621-29632.	3.4	74
40	A novel amino acid substitution of integrin Î±IIb in Glanzmann thrombasthenia confirms that the N-terminal region of the receptor plays a role in maintaining Î²-propeller structure. Platelets, 2013, 24, 77-80.	2.3	5
41	Glanzmann Thrombasthenia: State of the Art and Future Directions. Seminars in Thrombosis and Hemostasis, 2013, 39, 642-655.	2.7	84
42	Heterogeneity of Platelet Functional Alterations in Patients With Filamin A Mutations. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, e11-8.	2.4	52
43	Molecular Dynamics Analysis of a Novel Î²3 Pro189Ser Mutation in a Patient with Glanzmann Thrombasthenia Differentially Affecting Î±IIbÎ²3 and Î±vÎ²3 Expression. PLoS ONE, 2013, 8, e78683.	2.5	7
44	Gray platelet syndrome and defective thrombo-inflammation in Nbeal2-deficient mice. Journal of Clinical Investigation, 2013, 123, 3331-3342.	8.2	151
45	Deep Vein Thrombosis, Raynaud's Phenomenon, and Prinzmetal Angina in a Patient with Glanzmann Thrombasthenia. Case Reports in Hematology, 2012, 2012, 1-4.	0.4	6
46	Two Types of Procoagulant Platelets Are Formed Upon Physiological Activation and Are Controlled by Integrin Î± _{IIb} Î² ₃. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 2475-2483.	2.4	46
47	Understanding the genetic basis of Glanzmann thrombasthenia: implications for treatment. Expert Review of Hematology, 2012, 5, 487-503.	2.2	42
48	Exome sequencing identifies NBEAL2 as the causative gene for gray platelet syndrome. Nature Genetics, 2011, 43, 735-737.	21.4	245
49	Platelets, inflammation and tissue regeneration. Thrombosis and Haemostasis, 2011, 105, S13-S33.	3.4	593
50	Thrombocytopenia resulting from mutations in filamin A can be expressed as an isolated syndrome. Blood, 2011, 118, 5928-5937.	1.4	148
51	Glanzmann thrombasthenia: a review of ITGA2B and ITGB3 defects with emphasis on variants, phenotypic variability, and mouse models. Blood, 2011, 118, 5996-6005.	1.4	194
52	Founder effect and estimation of the age of the French Gypsy mutation associated with Glanzmann thrombasthenia in Manouche families. European Journal of Human Genetics, 2011, 19, 981-987.	2.8	33
53	Glanzmann Thrombasthenia-Like Syndromes Associated with Macrothrombocytopenias and Mutations in the Genes Encoding the Î±IIbÎ²3 Integrin. Seminars in Thrombosis and Hemostasis, 2011, 37, 698-706.	2.7	53
54	Are bone defects in rare patients with Glanzmann's thrombasthenia associated withITGB3orITGA2Bmutations?. Platelets, 2011, 22, 547-551.	2.3	3

#	Article	IF	Citations
55	A Novel Leukocyte Adhesion Deficiency III Variant: Kindlin-3 Deficiency Results in Integrin- and Nonintegrin-Related Defects in Different Steps of Leukocyte Adhesion. Journal of Immunology, 2011, 186, 5273-5283.	0.8	59
56	Abnormal VWF modifies megakaryocytopoiesis: studies of platelets and megakaryocyte cultures from patients with von Willebrand disease type 2B. Blood, 2010, 115, 2649-2656.	1.4	71
57	Phosphatidylserine exposure and other apoptoticâ€like events in Bernardâ€Soulier syndrome platelets. American Journal of Hematology, 2010, 85, 584-592.	4.1	29
58	Thrombocytopenia after abciximab use results from different mechanisms. Thrombosis and Haemostasis, 2010, 103, 651-661.	3.4	23
59	Rapid diagnosis of the French gypsy mutation in Glanzmann thrombasthenia using high-resolution melting analysis. Thrombosis and Haemostasis, 2010, 104, 1076-1077.	3.4	11
60	A unique combination of inhibitory and partially activating mutations in Î²3 of a patient with variant-type Glanzmann thrombasthenia. Platelets, 2010, 21, 498-500.	2.3	2
61	Gray platelet syndrome: natural history of a large patient cohort and locus assignment to chromosome 3p. Blood, 2010, 116, 4990-5001.	1.4	137
62	Tissue inhibitors of matrix metalloproteinases in platelets and megakaryocytes: A novel organization for these secreted proteins. Experimental Hematology, 2009, 37, 849-856.	0.4	61
63	New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura. Lancet, The, 2009, 373, 1562-1569.	13.7	65
64	Activation of Î±IIbÎ²3 is a sufficient but also an imperative prerequisite for activation of Î±2Î²1 on platelets. Blood, 2007, 109, 595-602.	1.4	43
65	The gray platelet syndrome: Clinical spectrum of the disease. Blood Reviews, 2007, 21, 21-36.	5.7	201
66	Platelet-associated CD154 in immune thrombocytopenic purpura. Blood, 2005, 105, 215-218.	1.4	101
67	Severe deficiency of glycoprotein VI in a patient with gray platelet syndrome. Blood, 2004, 104, 107-114.	1.4	83
68	Human IgG Monoclonal Anti-Î±IIbÎ²3-Binding Fragments Derived from Immunized Donors Using Phage Display. Journal of Immunology, 2002, 168, 2035-2045.	0.8	30
69	A novel 196 Leu to Pro substitution in the Î²3 subunit of the Î±IIbÎ²3 integrin in a patient with a variant form of Glanzmann thrombasthenia. Platelets, 2002, 13, 101-111.	2.3	18
70	Analysis of the Amino Acid Requirement for a Normal Î±IIbÎ²3 Maturation at Î±IIbGlu324 Commonly Mutated in Glanzmann Thrombasthenia. Thrombosis and Haemostasis, 2002, 88, 655-662.	3.4	25
71	Detection of Transfused Platelets in a Patient with Glanzmann Thrombasthenia. Thrombosis and Haemostasis, 2002, 87, 543-544.	3.4	18
72	Reduced Collagen-Induced Platelet Aggregation in Obligate Heterozygotes of a Glanzmann Thrombasthenia Variant with a Î²3 Mutation. Thrombosis and Haemostasis, 2002, 88, 364-365.	3.4	3

#	Article	IF	Citations
73	Absence of GPIbÎ± is responsible for aberrant membrane development during megakaryocyte maturation. Experimental Hematology, 2002, 30, 352-360.	0.4	86
74	A Ser752â†'Pro substitution in the cytoplasmic domain of Î²3 in a Glanzmann thrombasthenia variant fails to prevent interactions between the Î±IIbÎ²3 integrin and the platelet granule pool of fibrinogen. British Journal of Haematology, 2002, 118, 1143-1151.	2.5	11
75	Reduced collagen-induced platelet aggregation in obligate heterozygotes of a Glanzmann thrombasthenia variant with a beta 3 mutation. Thrombosis and Haemostasis, 2002, 88, 364-5.	3.4	1
76	Analysis of the amino acid requirement for a normal alphaIIbbeta3 maturation at alphaIIbGlu324 commonly mutated in Glanzmann thrombasthenia. Thrombosis and Haemostasis, 2002, 88, 655-62.	3.4	3
77	A point mutation in the cysteine-rich domain of glycoprotein (GP) IIIa results in the expression of a GPIIb-IIIa (Î±IIbÎ²3) integrin receptor locked in a high-affinity state and a Glanzmann thrombastheniaâ€"like phenotype. Blood, 2001, 98, 2432-2441.	1.4	104
78	Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature, 2001, 409, 202-207.	27.8	1,338
79	Characterization of Inherited Differences in Transcription of the Human Integrin Î±2 Gene. Journal of Biological Chemistry, 2001, 276, 23518-23524.	3.4	41
80	Labeling of the Internal Pool of GP IIb-IIIa in Platelets by c7E3 Fab Fragments (abciximab): Flow and Endocytic Mechanisms Contribute to the Transport. Blood, 1999, 93, 1622-1633.	1.4	56
81	Platelet Glycoprotein IIb/IIIa Inhibitors. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 2835-2840.	2.4	57
82	Homozygous Cys542Arg substitution in GPIIIa in a Swiss patient with type I Glanzmann's thrombasthenia. British Journal of Haematology, 1999, 105, 523-531.	2.5	28
83	Autoimmune thrombocytopenic purpura (AITP) and acquired thrombasthenia due to autoantibodies to GP IIbâ€"IIIa in a patient with an unusual platelet membrane glycoprotein composition. , 1998, 57, 164-175.		13
84	Double heterozygosity of the GPIIb gene in a Swiss patient with Glanzmann's thrombasthenia. British Journal of Haematology, 1998, 102, 918-925.	2.5	27
85	Screening for factor V Leiden and a prothrombin gene polymorphism in patients with Glanzmann's thrombasthenia. British Journal of Haematology, 1998, 101, 593-594.	2.5	4
86	Ultrastructural analysis of the distribution of the vitronectin receptor (Î± v Î² 3) in human platelets and megakaryocytes reveals an intracellular pool and labelling of the Î±â€granule membrane. British Journal of Haematology, 1997, 96, 823-835.	2.5	38
87	PAICA: A Method for Characterizing Platelet-Associated Antibodies - Its Application to the Study of Idiopathic Thrombocytopenic Purpura and to the Detection of Platelet-bound c7E3. Thrombosis and Haemostasis, 1996, 76, 1020-1029.	3.4	33
88	Bilateral linkage between a new deletion polymorphism in intron 21 of the GP Ib gene and the HPA-3b (Bakb) determinant. British Journal of Haematology, 1995, 91, 747-751.	2.5	17
89	Two human antibodies reacting with different epitopes on integrin beta3 of platelets and endothelial cells. FEBS Journal, 1994, 222, 743-751.	0.2	33
90	Distribution of glycoprotein IIb-IIIa complexes in the surface membranes of human platelets and megakaryocytes. British Journal of Haematology, 1985, 59, 171-182.	2.5	27

#	Article	IF	Citations
91	Molecular Defects in Interactions of Platelets with the Vessel Wall. New England Journal of Medicine, 1984, 311, 1084-1098.	27.0	378
92	Relationship between Fibrinogen Binding and the Platelet Glycoprotein Deficiencies in Glanzmann's Thrombasthenia Type I and Type II. British Journal of Haematology, 1981, 48, 47-57.	2.5	99
93	Immunochemical Evidence for Protein Abnormalities in Platelets from Patients with Glanzmann's Thrombasthenia and Bernard-Soulier Syndrome. Journal of Clinical Investigation, 1980, 65, 722-731.	8.2	167